Introduction

Adeno-associated virus (AAV) vectors have become a cornerstone of gene therapy, valued for their safety, broad targeting capabilities, and adaptability across therapeutic applications.

As development advances from research to process refinement, reliable quantification of total AAV capsid concentration is key to maintaining consistency and supporting informed decision-making.

Traditional methods such as ELISA can be time-consuming, serotype-specific, and sensitive to sample complexity. The Amperia™ platform offers a streamlined alternative – using a sandwich-format assay with high-affinity antibodies from Thermo Fisher Scientific to quantify multiple AAV serotypes with robust performance across sample types. With sensor-based detection and fast turnaround, Amperia enables consistent results in day-to-day workflows.

Assay format & workflow

Amperia™ uses a sandwich assay format for AAV capsid quantification. The sensor surface presents anti-AAV capture sites, typically formed via streptavidin–biotin interaction. AAV particles in the sample bind to this immobilised capture antibody, followed by the addition of a labelled detection antibody specific to the AAV capsid.

As AAV concentration increases, more detection antibody is retained at the sensor surface, generating a stronger signal. This direct signal response supports reliable quantification across a range of sample types, including clarified lysates and crude supernatants.

Assays are run through the system’s touchscreen-guided workflow, using protocol templates tailored for different sample numbers. With intuitive setup and integrated analysis, Amperia enables reproducible AAV titre measurement without the complexity of traditional immunoassays.

Assay Workflow Schematic. (1) Sensor surface with streptavidin coating. (2) Capture antibody binding via biotin-streptavidin interaction. (3) AAV capsid captured by the immobilized antibody. (4) Detection antibody (HRP-conjugated) binds the captured capsid, enabling signal generation.

*AAVX Kit (AK-AAV-002) validated on AAV2, AAV5, AAV6, AAV8. AAV9 supported via dedicated kit (AK-AAV-003)

Note:

Values shown are typical ranges based on internal testing. Actual throughput and hands-on time may vary depending on assay format, sample type, and workflow configuration. Detection range may vary depending on analyte affinity and assay conditions.

Data highlights

Amperia™ delivers consistent and reproducible quantification across multiple AAV serotypes. The AAVX Total Capsid Quantification Kit is designed for broad serotype compatibility, while the AAV9-specific kit enables accurate measurement of AAV9 particles. Both kits support use with purified and crude sample matrices, offering flexibility across diverse gene therapy workflows.

Representative standard curves generated using the AAVX Total Capsid Quantification Kit (AAV2, AAV5, AAV6, AAV8) and the AAV9 Total Capsid Quantification Kit.

Where Amperia™ supports AAV workflows

Amperia™ supports a range of AAV-related workflows, providing fast and reproducible quantification across different sample types and development stages.

Summary

Amperia provides a streamlined and scalable solution for AAV quantification – combining sensor-based detection, guided workflows, and broad serotype coverage. Powered by Thermo Fisher’s CaptureSelect™ antibodies, the assay delivers reliable performance across sample types. It offers a practical alternative to traditional methods when speed, simplicity, and reproducibility matter most.

Relevant products

• AAVX Total Capsid Quantification Kit: AK-AAV-002
• AAV9 Total Capsid Quantification Kit: AK-AAV-003